Mpox Patient Journey in Israel

Tal Patalon*, Galit Perez, Yaki Saciuk, Ziva Refaeli, Sivan Gazit

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Reports on Mpox have, thus far, characterized the disease, but mostly through a single timepoint view. The aim of this study was to characterize Mpox in the Israeli setting, in general, alongside compiling a detailed patient journey from multiple in-depth interviews with infected individuals. This descriptive study followed two complimentary paths: retrospective and prospective. The first consisted of interviews with Mpox patients, while the retrospective part included the retrieval of anonymized electronic medical records of patients diagnosed with Mpox between May and November 2022. Patient characteristics in Israel were, overall, comparable to global reports. We found that the median time from symptoms to first suspicion of Mpox was 3.5 days, while the median time from the first symptom to a confirmatory test was 6.5 days, which could explain the surge in Israel. The duration of lesions did not alter in terms of their anatomical location, while lower Ct values correlated both with a longer symptom duration and more symptoms. Most patients reported anxiety to a high degree. Clinical trials that consist of a long-term relationship with the medical researchers contribute greatly to a deeper understanding of the patient journey, especially for unfamiliar or stigmatized diseases. Emerging infections, such as Mpox, should be further investigated to assess asymptomatic carriers, especially when rapidly spreading.

Original languageEnglish
Article number1042
Issue number4
StatePublished - Apr 2023
Externally publishedYes


  • monkeypox
  • Mpox
  • MPX
  • Orthopoxvirus genus
  • patient journey


Dive into the research topics of 'Mpox Patient Journey in Israel'. Together they form a unique fingerprint.

Cite this